# RSV lower respiratory tract disease in infants

Condition · id `maternal:infant-rsv-disease` · Maternal & Newborn Atlas · release `fc5a600ec7387e71` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: RSV; Respiratory syncytial virus

Browse, life stage: Newborn; Infant follow-up  
Browse, care area: The baby's first year  

## In plain language

RSV (respiratory syncytial virus) is a common virus that usually causes a cold. In babies it can cause serious lung infections. Nearly all children catch RSV by age 2. There is no specific treatment for RSV infection. Two ways to protect babies from severe RSV illness are a vaccine given in pregnancy and an antibody injection given to the baby.

## Technical summary

Descriptions from MedlinePlus and FDA's 2023 news release; no incidence figures are recorded. FDA calls RSV the most frequent cause of lower respiratory tract illness in infants worldwide and, citing CDC, the leading cause of infant hospitalisation in the United States. The two prevention routes in this atlas are RSV vaccination in pregnancy and an antibody given to the infant; each has its own page. The recipient differs by route.

## Claims, with the population each applies to

## Context: Infants and young children and RSV (MedlinePlus and FDA descriptions)

Recipient: Child; Population: Infants and young children, the group MedlinePlus and FDA describe as most affected by serious RSV illness. The MedlinePlus page also covers older adults and people with weakened immune systems, who are outside this context.; Care setting: Not stated (general health information and an FDA news release).; Geography: General; the FDA statement about hospitalisation names the United States; Life stage: Infants from birth, and children up to about 2 years; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statements)

### MedlinePlus describes RSV as a common respiratory virus that usually causes mild, cold-like symptoms but can cause serious lung infections, especially in infants, and says nearly all children become infected with RSV by age 2. In very young infants the only symptoms may be irritability, decreased activity and trouble breathing. FDA's 2023 news release called RSV the most frequent cause of lower respiratory tract illness in infants worldwide and, citing the Centers for Disease Control and Prevention, the leading cause of infant hospitalisation in the United States.

- Category: Burden
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Infants and young children, the group MedlinePlus and FDA describe as most affected by serious RSV illness. The MedlinePlus page also covers older adults and people with weakened immune systems, who are outside this context.; Care setting: Not stated (general health information and an FDA news release).; Geography: General; the FDA statement about hospitalisation names the United States; Life stage: Infants from birth, and children up to about 2 years; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statements)
- Limitations: These are statements by a health information service and by FDA, not incidence studies, and neither gives numbers. The FDA statement about hospitalisation is FDA's report of a CDC statement; CDC's own source was not read.
- Last checked: 2026-10-15
- Sources:
  1. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, What is RSV?, sentences 1 and 2. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  2. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, What is RSV?, sentence 3. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  3. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, Who is at risk?, sentence 1 (part). Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  4. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, What are the symptoms?, paragraph 2. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  5. Supports: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants (FDA news release) (Regulator, edition Press announcement dated August 21, 2023. The page says its content was current as of 08/22/2023.) <https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>
     Locator: Paragraph 3, sentence 2. Retrieved 2026-10-15T13:49:54Z. Source state: Current. Snapshot hash: a9e38eeb5dbd394c4f249e8b4d31fc3c3355e93cb9f55b6dfe2607eb460623d9.
     How it applies: FDA news release.
  6. Supports: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants (FDA news release) (Regulator, edition Press announcement dated August 21, 2023. The page says its content was current as of 08/22/2023.) <https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>
     Locator: Paragraph 3, sentence 7. Retrieved 2026-10-15T13:49:54Z. Source state: Current. Snapshot hash: a9e38eeb5dbd394c4f249e8b4d31fc3c3355e93cb9f55b6dfe2607eb460623d9.
     How it applies: FDA news release.

### MedlinePlus says there is no specific treatment for RSV infection. It says there are two medicines to help prevent severe RSV illness in babies and young children, that these medicines cannot cure or treat children who already have RSV, and that one of them is given to infants who are younger than 8 months during their first RSV season.

- Category: Description
- Evidence stage: Guidance
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Infants and young children, the group MedlinePlus and FDA describe as most affected by serious RSV illness. The MedlinePlus page also covers older adults and people with weakened immune systems, who are outside this context.; Care setting: Not stated (general health information and an FDA news release).; Geography: General; the FDA statement about hospitalisation names the United States; Life stage: Infants from birth, and children up to about 2 years; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statements)
- Limitations: A plain-language summary. The page does not name the medicines. A monoclonal antibody for infants (nirsevimab) is on its own page, and the page's text on older children and on other prevention steps was not recorded here.
- Last checked: 2026-10-15
- Sources:
  1. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, What are the treatments?, sentence 1. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  2. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, Can RSV infections be prevented?, paragraph 3. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  3. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, Can RSV infections be prevented?, paragraph 3, sentence 2. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.
  4. Supports: Respiratory Syncytial Virus Infections (MedlinePlus health topic) (Webpage, edition The health topic page as shown on 2026-10-15. The page carries no edition date.) <https://medlineplus.gov/respiratorysyncytialvirusinfections.html>
     Locator: Summary, Can RSV infections be prevented?, paragraph 4, sentence 1. Retrieved 2026-10-15T13:49:53Z. Source state: Current. Snapshot hash: 234a38a10cca920623a2eae8c2ac85ffb8edeb6ee17a5f6b9fe58d976db69de7.
     How it applies: MedlinePlus health topic summary.

## Connected pages

- Filed under this front: Medicines and vaccines (`maternal:front-medicines-and-vaccines`)
- Related to: Vaccines in infancy and pregnancy (`maternal:infant-immunization`)
- Evaluated for this: Nirsevimab (`maternal:nirsevimab`) [a claim, not a settled fact; see claim `maternal:claim-melody-ma-rsv-lrti` and its context]
- Evaluated for this: Nirsevimab (`maternal:nirsevimab`) [a claim, not a settled fact; see claim `maternal:claim-melody-hospitalisation` and its context]
- Evaluated for this: RSV vaccination in pregnancy to protect the infant (`maternal:maternal-rsv-vaccination`) [a claim, not a settled fact; see claim `maternal:claim-matisse-severe-rsv-lrti-efficacy` and its context]
- Evaluated for this: RSV vaccination in pregnancy to protect the infant (`maternal:maternal-rsv-vaccination`) [a claim, not a settled fact; see claim `maternal:claim-matisse-any-rsv-lrti-90-days` and its context]

## Provenance

Content hash: 6ba87e682433602738a8e77130749c05fa763ee2e128318d6a94062e7559680f
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-15